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This volume is one of a series under the overall heading of
‘Progress in Inflammation Research’, this volume focusing on
cancer and inflammation. When I was a medical student, I was
very struck by the fact that chimney sweeps got cancer of the
scrotum and that some males with braces developed breast cancer.
Clearly, this has something to do with chronic irritation, if not
inflammation. In pathology lessons, reference was made to cancer
being a very heterogeneous disease with many different pheno-
types, although I remember reference to Virkhoff’s comment that
‘cancer is a wound that doesn’t cure’. Once on the wards, I was also
struck by the fact that people with chronic ulcerative colitis are 30-
to 50-fold more likely to develop cancer of the colon than patients
without ulcerative colitis. Bizarrely, we were taught that there was
no increased risk with another chronic inflammatory disease,
called Crohn’s disease, which we now know is far from the truth. It
is therefore surprising that the link between chronic irritation and
inflammation and the subsequent development of cancer has not
been given more prominence or recognised as a potential occums’
razor to explain the many different manifestations of cancer.
More recently, many authors have noted the association between
chronic infections and cancer and noted that they may well be
causally linked. Obvious examples include the induction of
hepatitis and hepatocellularcarcinoma by chronic infections of
hepatitis B virus and hepatitis C virus, as well as associations
between chronic bacterial infections, such as Helicobacter pylori
and stomach cancer. In this regard, Schistosomiasis has been a
recognised precursor of bladder cancer for many years.
This book explains all the various relationships between chronic
infection and inflammation and common tumours, focusing on
reflux oesophagitis and Barratt’s oesophagus and the association
with oesophageal cancer, asbestosis and mesothelioma, chronic
pancreatitis and pancreatic adenocarcinoma, in addition to other
infective agents, for example, human papilloma virus and cervical
cancer.
The first scientific chapter deals with cancer as a chronic
inflammatory disease and the role of immunotherapy. This is an
extremely informative chapter as cancer arises in an inflammatory
state but can be controlled by the appropriate induction of an
immune response, which itself requires a proinflammatory
cytokine production. This chapter deals with the fact that
there are several different types of stimulus given at different
times and this effects the final programming of T cells. For
example, a danger signal for a specific antigen, costimulation,
polarisation, localisation, termination, continuation and healing
process are all required to induce an effective and appropriate
immune response. It is of note that in a chronic inflammatory
process that there is active immune suppression of cell-mediated
immunity, which of course is required to contain any tumour
progression.
The next chapter looks at the very complicated network of
inflammatory chemokines and their role in tumour growth and
progression to help understand how they may lead to tumour
progression and how they may be manipulated to enhance an
immune response. It would certainly appear that they are involved
in tumour growth, vascularity and metastases and hence represent
potential therapeutic targets.
For a tumour to grow, evade and metastasis it has to be able to
dissolve normal tissues and this usually involves matrix metallo
proteinases (MMMPs) that are produced in inflammatory condi-
tions. There is a very delicate interaction and balancing act
between MMPs, inflammation and the development of cancer.
Certainly by the time a cancer has become evasive and
metastasised, there is an accepted need to inhibit MMP activity.
As such, this has been the target for several pharmaceutical
companies, and the failure to develop a significant nontoxic agent
eventually led to the demise of British biotech who had ‘hung their
hat’, so to speak, on this being the most important target in cancer.
In addition to chronic inflammation being associated with
downregulation of local cell-mediated immune response (which is
not always confined to the local environment as there is evidence
that even small tumours can suppress systemic cell mediated
immune responses), chronic inflammation enhances angiogenesis
as there is a requirement for increased repair and growth factors
resulting in increased vascularity. In a chapter on the interplay
between inflammation and tumour angiogenesis, Yang Song and
Nakarda explore the delicate balance as well as the problem that
tumour-associated macrophages are often a poor prognostic
marker producing a variety of cytokines, proteases, growth factors
and angiogenic factors, etc (in contrast, tumour infiltrating
lymphocytes are usually a good prognostic feature in most tumour
types). The role of this inflammation and the various pathways
involved, including the induction of adhesion molecules and
interaction with cell cycle inhibitors, is examined. This leads nicely
onto the fact that an end result of inflammation and proliferation
is apoptosis and the delicate balance between pro- and anti-
apoptotic genes. Apoptotic resistance is common in inflammation
and is obviously a risk factor in cancer and therefore also provides
a novel therapeutic approach.
It is important to be aware that there are many different
pathways involved in chronic inflammation; however, one of the
most consistent ones involves cyclooxygenase and the prostaglan-
din pathways. Cyclooxygenase-2 (COX-2) is induced essentially by
inflammation and as such drives proangiogenic activity and
reduces immune responsiveness. It is present in a wide variety
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metastases and therefore represents a very good target. Aspirin, of
course, is the simplest and cheapest of these agents and has
given us the evidence that reduction of chronic inflammation
will reduce the incidence of colorectal cancer in patients
with chronic inflammation, which includes adenomas and
polyps. There are two chapters on the links of cyclooxygenase
and cancer as well as the different approaches taken to inhibit
this enzyme in both the prevention and therapy of cancer. The last
footnote of this book quotes from a book called ‘Pattern
Recognition’ by William Gibson, who defines apophonia and the
spontaneous perception of connections and meaningfulness in
unrelated things.
This book does a brilliant job in putting in a fairly logical order
the links and association of chronic inflammation and cancer in
such a way that one can only wonder why it has not been used as
the template for research and understanding as well as the
development of new treatments for cancer before.
My only criticisms of this book are minor. Firstly, having
established a broad range of chronic inflammatory states and solid
tumours it is a pity that the editors have not asked whether this
would apply to all the major conditions. Examples, notable by their
absence, include lung cancer, which is always preceded by
histological, if not clinical, bronchitis for at least two decades.
There is also evidence that both prostate and breast cancer are
associated with various degrees of an inflammatory state. It is
certainly recognised that inflammatory breast cancer is a poor
prognostic feature.
The second criticism is that whereas tremendous detail has been
explored with regards to chemokines in a chapter by Fran Balkwell,
the interaction between many of the inflammatory factors and the
cell signalling pathways have not been explored in more detail as
there are certainly some fascinating molecular interactions; for
instance, in that they may help explain the contribution of the
famous Vogelstein progression from benign dyplasia through to
metastatic disease. Nevertheless, the compact size of this volume
makes it easy to read in one sitting as well as being a valuable
source of reference for anyone with a passing interest in the cause
and treatment of cancer.
AG Dalgleish
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